Strategic investment agreement · Biotech
MOLCURE signs investment agreement with Itochu
The partnership aims to connect AI drug discovery with support for nonclinical and clinical development.
Linking discovery to later development
MOLCURE’s molecular design technology will be paired with Itochu group’s pharmaceutical development services and business network. The partners intend to help pharmaceutical and biotechnology customers move candidates from discovery into subsequent development stages.
Itochu’s capabilities include A2 Healthcare, its wholly owned clinical development subsidiary. The announcement states that MOLCURE will receive an investment under the agreement; the amount and settlement date were not disclosed.
Funding history
Strategic investment agreement · This roundUndisclosed